J Nucl Med. 2008; 49 (Supplement 1):253P
General Clinical Specialties: General Practice-OncologyGeneral Practice-Oncology Posters |
Clinical value of FDG PET/CT in post-treatment surveillance of cervical cancer
Min Kyung Lee1,
Min ki Yoon1,
Kyung Hoon Hwang1,
Wonsick Choe1 and
Chan Yong Park2
1 Nuclear Medicine;
2 Obstetrics and Gynecology, Gil Medical Center, School of Medicine, Gachon University of Medicine and Science, Incheon, South Korea
1084
Objectives: We investigated the clinical value of PET/CT as a part of post-treatment surveillance modalities for detecting recurrent cervical cancer.
Methods: Ninety-three patients treated for cervical cancer were reviewed. All patients underwent F-18 FDG PET/CT for post-treatment surveillance. CT, MRI, or biopsy were also performed to confirm the positive lesions on the PET/CT.
Results: Sixty-eight patients (73.1%) had no abnormal lesion on PET/CT, and 67 patients of them (98.5%) were confirmed to have no evidence of disease. Twenty-five patients (26.9%) showed increased uptake on PET/CT and 20 patients (80%) were diagnosed as recurrence. The sensitivity and specificity were 95.2% and 93.1%. The NPV and PPV were 98.5% and 80%. For lesion-based analysis, total 44 lesions revealed increased FDG uptake, and 32 lesions were true positive. The sensitivity and PPV were 91.4% and 76.2%.
Conclusions: PET/CT may be a useful method in post-surveillance of cervical cancer patients for detecting recurrence.
| |
Patient based analysis
|
|
